Structure of Voglibose
CAS No.: 83480-29-9
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Voglibose, an N-substituted derivative of valiolamine, can inhibit α-glucosidase and be used to treat hyperglycemia and its concomitant diseases.
Synonyms: AO-128
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 83480-29-9 |
Formula : | C10H21NO7 |
M.W : | 267.28 |
SMILES Code : | O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](NC(CO)CO)C1 |
Synonyms : |
AO-128
|
MDL No. : | MFCD00865496 |
InChI Key : | FZNCGRZWXLXZSZ-CIQUZCHMSA-N |
Pubchem ID : | 444020 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02456428 | - | Completed | - | Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less << | |
NCT02476760 | - | Completed | - | Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less << | |
NCT02685410 | HIV Prevention ... More >> STI Prevention Less << | Not Applicable | Completed | - | United States, Connecticut ... More >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 Less << |
NCT03157895 | Relationship, Family (Foster) ... More >> Substance Use Prevention Less << | Not Applicable | Recruiting | January 31, 2020 | United States, Washington ... More >> Social Development Research Group Recruiting Seattle, Washington, United States, 98115 Contact: Jessica Colito, MSW 206-221-5250 jcolito@uw.edu Contact: Patricia Gomez 206-616-7931 pagomez@uw.edu Principal Investigator: Kevin Haggerty, PhD Sub-Investigator: Susan Barkan, PhD Less << |
NCT02475499 | - | Completed | - | Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less << | |
NCT00985400 | Colorectal Cancer | Not Applicable | Active, not recruiting | November 2020 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 Less << |
NCT00454766 | - | Active, not recruiting | February 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << | |
NCT00853203 | - | Active, not recruiting | January 2019 | United States, Texas ... More >> Kelsey-Seybold Clinics Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << | |
NCT01504919 | Psychosocial Problem | Not Applicable | Active, not recruiting | January 2019 | United States, Texas ... More >> William Marsh Rice University Houston, Texas, United States, 77005 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01311856 | - | Active, not recruiting | March 2020 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << | |
NCT00473798 | - | Active, not recruiting | July 2020 | United States, Texas ... More >> Hermann Professional Building Clinic Houston, Texas, United States, 77030 LBJ Hospital Houston, Texas, United States, 77030 Texas Medical Center Clinic Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, British Columbia Vancouver General Hospital/British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5Z 1M9 Less << | |
NCT00533338 | Breast Cancer | Not Applicable | Active, not recruiting | July 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01504789 | Breast Cancer | Not Applicable | Active, not recruiting | February 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Puerto Rico University of Puerto Rico San Juan, Puerto Rico, 00936 Less << |
NCT02774759 | Malignant Neoplasms of Female ... More >>Genital Organs Less << | Not Applicable | Active, not recruiting | October 2020 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT00633633 | Heart Failure | Not Applicable | Active, not recruiting | February 2021 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78249 Less << |
NCT01697592 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | - |
NCT00501761 | - | Active, not recruiting | May 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << | |
NCT01646788 | Obstructive Lesions of Arterio... More >>venous Dialysis Fistulae Less << | Not Applicable | Unknown | January 2015 | Israel ... More >> The Rabin Medical Center, Hasharon Hospital Not yet recruiting Petah Tikva, Israel Less << |
NCT00542438 | Cardiovascular Disease | Not Applicable | Active, not recruiting | October 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02593422 | Ovarian Cancer | Not Applicable | Completed | - | United States, Maryland ... More >> University of Maryland, College Park College Park, Maryland, United States, 20742 Less << |
NCT02194387 | Breast Cancer ... More >> Ovarian Cancer Less << | Not Applicable | Recruiting | September 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less << |
NCT01682824 | - | Active, not recruiting | May 31, 2019 | United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << | |
NCT01242202 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... More >> Chubu, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan Less << |
NCT01263470 | - | Completed | - | - | |
NCT01697592 | - | Completed | - | - | |
NCT02287402 | Impaired Glucose Tolerance (IG... More >>T) Less << | PHASE4 | COMPLETED | 2025-11-12 | - |
NCT01263470 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | Japan ... More >> Okayama, Japan, 701-0192 Less << |
NCT02287402 | Impaired Glucose Tolerance (IG... More >>T) Less << | PHASE4 | COMPLETED | 2025-11-12 | - |
NCT00724542 | Coronary Heart Disease ... More >> Impaired Glucose Tolerance Less << | Not Applicable | Unknown | December 2010 | China, Beijing ... More >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100034 Contact: Wenhui Ding, Professor 86-10-66551122 ext 5001 dwh_rd@126.com Less << |
NCT01263496 | Type 2 Diabetes Mellitus | Phase 2 | Completed | - | - |
NCT02097342 | Type 2 Diabetes Mellitus ... More >> Insulin Sensitivity/Resistance Less << | Phase 4 | Unknown | January 2015 | India ... More >> Postgraduate Institute of Medical Education & Research Recruiting Chandigarh, India, 160012 Contact: Anil Bhansali, MD DM anilbhansaliendocrine@gmail.com Less << |
NCT00970528 | Diabetes Mellitus, Type 2 | Phase 4 | Completed | - | Korea, Republic of ... More >> Wonju-si, Gang''weondo, Korea, Republic of, 220-701 Busan, Korea, Korea, Republic of, 602-714 Gyeonggi-do, Korea, Korea, Republic of, 463-500 Gyeonggi-do, Korea, Korea, Republic of, 471-701 Pusan, Korea, Korea, Republic of, 602-739 Seoul, Korea, Korea, Republic of, 150-713 Daegu, Korea, Republic of, 705-717 Jeonju-si, Korea, Republic of, 456-712 Seongbuk-gu Seoul, Korea, Republic of, 136-705 Seoul, Korea, Republic of, 134-701 Seoul, Korea, Republic of, 135-710 Less << |
NCT01263496 | - | Completed | - | - | |
NCT00212017 | Impaired Glucose Tolerance ... More >> Myocardial Infarction Less << | Not Applicable | Terminated(We obtained the fin... More >>al results due to the interim analysis.) Less << | - | Japan ... More >> National Cardiovascular Center Suita, Osaka, Japan, 565-8565 Less << |
NCT03546972 | Obesity and Other Hyperaliment... More >>ation Less << | Not Applicable | Recruiting | November 2019 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact kbasenen@mdanderson.org Less << |
NCT01263483 | Type 2 Diabetes Mellitus | Phase 2 Phase 3 | Completed | - | - |
NCT01263509 | Type 2 Diabetes Mellitus | Phase 2 Phase 3 | Completed | - | - |
NCT01263483 | - | Completed | - | - | |
NCT00411554 | Diabetes Mellitus, Non-Insulin... More >>-Dependent Less << | Phase 3 | Completed | - | - |
NCT01263509 | - | Completed | - | - | |
NCT00411554 | - | Completed | - | - | |
NCT00654381 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | Japan ... More >> 1218.23.05 Boehringer Ingelheim Investigational Site Asahi, Chiba, Japan 1218.23.06 Boehringer Ingelheim Investigational Site Funabashi, Chiba, Japan 1218.23.21 Boehringer Ingelheim Investigational Site Hitachinaka, Ibaraki, Japan 1218.23.44 Boehringer Ingelheim Investigational Site Hitachiota, Ibaraki, Japan 1218.23.09 Boehringer Ingelheim Investigational Site Imizu, Toyama, Japan 1218.23.45 Boehringer Ingelheim Investigational Site Inashiki-gun, Ibaraki, Japan 1218.23.13 Boehringer Ingelheim Investigational Site Izumisano, Osaka, Japan 1218.23.27 Boehringer Ingelheim Investigational Site Kariya, Aichi, Japan 1218.23.47 Boehringer Ingelheim Investigational Site Kitakatsushika-gun, Saitama, Japan 1218.23.39 Boehringer Ingelheim Investigational Site Kitakyuushuu, Fukuoka, Japan 1218.23.02 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.03 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.10 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1218.23.37 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.38 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.23 Boehringer Ingelheim Investigational Site Matsumoto, Nagano, Japan 1218.23.07 Boehringer Ingelheim Investigational Site Meguro-ku, Tokyo, Japan 1218.23.25 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.26 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.28 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.29 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.30 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.04 Boehringer Ingelheim Investigational Site Naka, Ibaraki, Japan 1218.23.15 Boehringer Ingelheim Investigational Site Nishi-ku, Hiroshima, Hiroshima, Japan 1218.23.34 Boehringer Ingelheim Investigational Site Nishi-ku, Sakai, Osaka, Japan 1218.23.22 Boehringer Ingelheim Investigational Site Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan 1218.23.16 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.40 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.36 Boehringer Ingelheim Investigational Site Okayama, Okayama, Japan 1218.23.11 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.12 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.32 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.33 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.35 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.17 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.18 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.19 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.41 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.42 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.43 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.01 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.20 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.46 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan 1218.23.08 Boehringer Ingelheim Investigational Site Shinjyuku-ku,Tokyo, Japan 1218.23.14 Boehringer Ingelheim Investigational Site Suita, Osaka, Japan 1218.23.31 Boehringer Ingelheim Investigational Site Takatsuki, Osaka, Japan 1218.23.48 Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan Less << |
NCT00837577 | - | Completed | - | - | |
NCT01309698 | Type 2 Diabetes | Phase 4 | Completed | - | Japan ... More >> Novartis Investigative Site Tokyo, Japan Less << |
NCT00654381 | - | Completed | - | - | |
NCT00368134 | Diabetes Mellitus, Type 2 | Phase 3 | Completed | - | Japan ... More >> Novartis Pharmaceuticals Tokyo, Japan Less << |
NCT01055652 | Type 2 Diabetes Mellitus | Phase 1 | Completed | - | Japan ... More >> Research Site Moriya, Japan Research Site Osaka, Japan Less << |
NCT02049814 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | China, Anhui ... More >> Hefei, Anhui, China Maanshan, Anhui, China China, Beijing Beijing, Beijing, China China, Guangdong Guangzhou, Guangdong, China Shenzhen, Guangdong, China Taishan, Guangdong, China China, Hunan Zhuzhou, Hunan, China China, Jiangsu Nanjing, Jiangsu, China Xuzhou, Jiangsu, China China, Jilin Changchun, Jilin, China Jilin, Jilin, China China, Liaoning Shenyang, Liaoning, China China, Shandong Qingdao, Shandong, China China, Shanghai Shanghai, Shanghai, China China, Shanxi Yan An, Shanxi, China Yanan, Shanxi, China China, Tianjin Tianjin, Tianjin, China China, Zhejiang Wenzhou, Zhejiang, China Less << |
NCT01993927 | Impaired Glucose Tolerance | COMPLETED | 2013-08-31 | Osaka, Japan | |
NCT01993927 | Impaired Glucose Tolerance | COMPLETED | 2013-08-31 | Osaka, Japan | |
NCT00663884 | Diabetes Mellitus, Type 2 | Phase 4 | Completed | - | Korea, Republic of ... More >> The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital Seoul, Korea, Republic of, 137-701 Less << |
NCT00837577 | Diabetes Mellitus, Non-Insulin... More >>-Dependent Less << | Phase 3 | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.74mL 0.75mL 0.37mL |
18.71mL 3.74mL 1.87mL |
37.41mL 7.48mL 3.74mL |
|
Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|